top of page
WIN-B
OFFICIAL TITLE: CLINICAL STUDY TO EVALUATE DEBIO0123 + SACITUZUMAB GOVITECAN COMBINATION IN TNBC OR HR+/​HER2- ADVANCED BREAST CANCER (WIN-B)
Breast cancer
Ib/II
74
8
Spain, Uk & US
Set-up
CLINICAL TRIAL DETAILS
THE PRIMARY OBJECTIVE IS TO EVALUATE DEBIO 0123'S RP2D WHEN ADMINISTERED IN COMBINATION WITH SACITUZUMAB GOVITECAN, SAFETY AND EFFICACY OF THIS COMBINATION THERAPY IN ADVANCED/METASTATIC BREAST CANCER PATIENTS. PATIENTS AGED ≥ 18 YEARS WITH TNBC OR HR+/HER2- ADVANCED/METASTATIC BREAST CANCER RELAPSING AFTER ONE OR TWO LINES OF TREATMENT ARE ELIGIBLE TO PARTICIPATE IN THE STUDY.
WIN-B AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
TRIAL RESUME
WIN-B SITES
SPAIN
Arnau de Vilanova de Valencia
SPAIN
Hospital Beata María Ana
SPAIN
Hospital Universitario Virgen de la Victoria
UK
Beatson West of
SPAIN
Hospital Universitari Dexeus
SPAIN
Hospital Universitario Clínico San Cecilio de Granada
UK
Velindre University NHS Trust
UK
Hospital Universitario San Juan Alicante
bottom of page